TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31627746

Group type: EXPERIMENTAL
Intervention: Chemotherapy and surgery
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Surgery arm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trial participation
Number of subjects: 15
Study: 31628118

Group type: EXPERIMENTAL
Intervention: Fast decline in eGFR (lowest quartile of eGFR slope -4.1 ml/min per 1.73 m²)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Baseline eGFR (median 73 ml/min per 1.73 m²)
Number of subjects: 833
Study: 31628130

Group type: EXPERIMENTAL
Intervention: Seven biomarkers (NR2, NR2 antibodies, PARK7, NDKA, UFD1, B-FABP, H-FABP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Clinical predictors of TIA/minor stroke
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Addition of individual biomarkers
Number of subjects: 206
Study: 31628218

Group type: EXPERIMENTAL
Intervention: Optical molecular imaging using Bevacizumab-800CW for evaluating circumferential resection margins (CRM) after surgical resection.
Number of subjects: 0
Study: 31628489

Group type: EXPERIMENTAL
Intervention: White coat hypertension (office BP ≥ 135/85 mmHg and mean home BP < 130/80 mmHg)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Chronic hypertension (pre-pregnancy hypertension with office BP ≥ 135/85 mmHg and home BP ≥ 130/80 mmHg)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Normotension
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Higher pre-pregnancy BMI
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Higher home BP
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Higher prevalence of type 2 diabetes
Number of subjects: 222
Study: 31628588

Group type: EXPERIMENTAL
Intervention: Perceived discrimination due to criminal record
Number of subjects: 743
Study: 31628667

Group type: EXPERIMENTAL
Intervention: Intradermal injection of mixed methylene blue compound
Number of subjects: 118
Study: 31628852

Group type: EXPERIMENTAL
Intervention: Bishop score <6
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Bishop score <6 in group 1
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Bishop score <6 in group 2
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Groups 1, 2, and 3 (largest contributors to overall cesarean rate)
Number of subjects: 3042
Study: 31628986

Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node technique using 200 microliters of saline solution containing 37 MBq of technetium-99m nanocolloid followed by 0.5 mL of indocyanine green (ICG) injected subperitoneally.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel lymph node technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of technetium-99m nanocolloid and indocyanine green (ICG) for sentinel lymph node identification
Number of subjects: 30
Study: 31629403

Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI) - Group I (40 subjects) with mild speech impairment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI) - Group II (23 subjects) with moderate and profound speech deficits
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Frenchay Dysarthria Assessment (FDA) - Group I (40 subjects) with mild speech impairment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Frenchay Dysarthria Assessment (FDA) - Group II (23 subjects) with moderate and profound speech deficits
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall assessment using VHI and FDA
Number of subjects: 63
Study: 31629406

Group type: EXPERIMENTAL
Intervention: Long-DM group (≥10 years of DM)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Non-DM group
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Short-DM group (<10 years of DM)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 279

Group type: COMPARATOR
Intervention: Patients without DM
Number of subjects: 279
Study: 31629746

Group type: EXPERIMENTAL
Intervention: Dedicated transcaval closure device (TCD)
Number of subjects: 12
Study: 31630102

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anatomic landmark method
Number of subjects: 0
Study: 31630177

Group type: EXPERIMENTAL
Intervention: Presence of pleural adhesions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: VE/VCO2 slope
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Logistic regression for pleural adhesions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Logistic regression for VE/VCO2 slope
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: AUC for predicting PAL
Number of subjects: 96
Study: 31630414

Group type: EXPERIMENTAL
Intervention: TVB-2640
Number of subjects: 12
Study: 31630601

Group type: EXPERIMENTAL
Intervention: Renal Venous Stasis Index (RVSI)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for composite end point
Number of subjects: 205
Study: 31630886

Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug (type I and type II) used in SAPE procedures
Number of subjects: 101
Study: 31631693

Group type: EXPERIMENTAL
Intervention: Coll2-1 measurement in serum using an immunoassay
Number of subjects: 131

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 131
Study: 31631825

Group type: EXPERIMENTAL
Intervention: Potentially modifiable facilitators and barriers identified from the perspectives of patients, carers, and physicians.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrument for the combined assessment of multiple key facilitators and barriers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantification of the effect of facilitators and barriers on the duration of untreated illness (DUI).
Number of subjects: 0
Study: 31631961

Group type: EXPERIMENTAL
Intervention: SBA-RS
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Retinoscopy
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Retinomax
Number of subjects: 470
Study: 31632000

Group type: EXPERIMENTAL
Intervention: Revefenacin
Number of subjects: 0
Study: 31632154

Group type: EXPERIMENTAL
Intervention: Extended-release guaifenesin 1200 mg (Mucinex)
Number of subjects: 552
Study: 31632285

Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Number of subjects: 0
Study: 31632316

Group type: EXPERIMENTAL
Intervention: Endotoxin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31632387

Group type: EXPERIMENTAL
Intervention: Agonistic autoantibodies (agAAb) activating the β2-adrenergic receptor
Number of subjects: 0
Study: 31633999

Group type: EXPERIMENTAL
Intervention: Data quality control strategy applied to clinically relevant parameters
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Data quality control strategy applied to established prognosticators
Number of subjects: 300
Study: 31634044

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM vaccine
Number of subjects: 3939
Study: 31634236

Group type: EXPERIMENTAL
Intervention: Laryngoscopy following endotracheal intubation
Number of subjects: 100
Study: 31634407

Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation (PNS) therapy
Number of subjects: 109
Study: 31634515

Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 30 daily sessions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 17
Study: 31635961

Group type: EXPERIMENTAL
Intervention: Manual segmentation and three-dimensional modeling software for renal volume measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Renal volume measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of total renal volume (TRV)
Number of subjects: 85
Study: 31636050

Group type: EXPERIMENTAL
Intervention: Patients with lymphedema undergoing complete decongestive therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients with lower limb lymphedema
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients with upper limb lymphedema
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients with OSA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients with lymphedema
Number of subjects: 43
Study: 31636081

Group type: EXPERIMENTAL
Intervention: Lung diffusion capacity for carbon monoxide and nitric oxide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise-induced changes in arterial oxygen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Skeletal muscle oxidation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison with healthy control subjects
Number of subjects: 16
Study: 31636342

Group type: EXPERIMENTAL
Intervention: Rituximab; specific dosage and duration not available
Number of subjects: 0
Study: 31636690

Group type: EXPERIMENTAL
Intervention: WSP-EN (white sweet potato enteral nutrition formula)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-WSP-EN (standard polymeric formulas)
Number of subjects: 54
Study: 31636713

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Sham-acupuncture (SA)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Comparison between EA and SA
Number of subjects: 1075
Study: 31636770

Group type: EXPERIMENTAL
Intervention: CHAMPS questionnaire (Canadian French version)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CHAMPS questionnaire, Short Form-36 (SF-36), St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 147
Study: 31637366

Group type: EXPERIMENTAL
Intervention: Parent perceptions of child-level food security status via the 8-item child-referenced Household Food Security Survey Module
Number of subjects: 2408

Group type: EXPERIMENTAL
Intervention: Child perceptions of child-level food security status via the 5-item Child Food Security Assessment
Number of subjects: 2408
Study: 31637440

Group type: EXPERIMENTAL
Intervention: T1D with IAH (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T1D with NAH (n=12)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HC (n=18)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T1D-IAH (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: T1D-NAH (n=12)
Number of subjects: 40
Study: 31637669

Group type: EXPERIMENTAL
Intervention: Olaparib (tablet 100 mg bid days 3-12) combined with carboplatin (AUC 4) and paclitaxel (175 mg/m2)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Olaparib (capsule and tablet formulations) using intermittent schedules (2 to 10 days of a 21-day cycle) combined with carboplatin/paclitaxel
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Olaparib combined with carboplatin/paclitaxel
Number of subjects: 132
Study: 31638578

Group type: EXPERIMENTAL
Intervention: Retrograde PCI
Number of subjects: 4201

Group type: COMPARATOR
Intervention: Antegrade-only PCI
Number of subjects: 4201
Study: 31638652

Group type: COMPARATOR
Intervention: Rivaroxaban 15 mg
Number of subjects: 25000

Group type: COMPARATOR
Intervention: Dabigatran 110 mg
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 25000
Study: 31638915

Group type: EXPERIMENTAL
Intervention: Culturally-adapted Depression Education Intervention (DEI)
Number of subjects: 350
Study: 31638967

Group type: EXPERIMENTAL
Intervention: Implementation Process Assessment Tool (IPAT)
Number of subjects: 0
Study: 31639033

Group type: EXPERIMENTAL
Intervention: Rescue fecal microbiota transplantation (FMT)
Number of subjects: 18
Study: 31639039

Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C) at doses of 10 mg/kg to 20 mg/kg every 2 weeks until disease progression or intolerable side effects
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Number of subjects: 8
Study: 31639054

Group type: EXPERIMENTAL
Intervention: Adapted Recent Life Changes Questionnaire (RLCQ) with a cut-off of 750 for common mental disorders (depression and anxiety)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adapted Recent Life Changes Questionnaire (RLCQ) with a cut-off of 800 for serious mental disorders (suicide, bipolar, dysthymia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Agreement between two psychologists using the Mini International Neuropsychiatric Interview (MINI)
Number of subjects: 0
Study: 31639066

Group type: EXPERIMENTAL
Intervention: Intensity modulated whole abdominal radiotherapy (WART)
Number of subjects: 20
Study: 31639132

Group type: EXPERIMENTAL
Intervention: Sarcopenic patients
Number of subjects: 83
Study: 31639692

Group type: EXPERIMENTAL
Intervention: Mutant 4D4 (L3-2) antibody-assisted assay
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Calculated nPSA (CN)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mutant 4D4 (L3-2) assay
Number of subjects: 105

Group type: COMPARATOR
Intervention: Reference wild-type (wt)-4D4-based assays
Number of subjects: 105
Study: 31640456

Group type: EXPERIMENTAL
Intervention: Patients with cancer (n=37)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Patients without cancer (n=81)
Number of subjects: 118
Study: 31640466

Group type: EXPERIMENTAL
Intervention: Plaque erosion diagnosis
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation-ACS
Number of subjects: 1241
Study: 31640565

Group type: EXPERIMENTAL
Intervention: Postoperative patient-controlled intravenous analgesia (PCIA) with 0.2 mg/kg hydromorphone and 4 mg/kg flurbiprofen; pump programmed as 2.0 mL/h background infusion with a loading dose of 1 mL and a lockout period of 15 min
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Postoperative patient-controlled intravenous analgesia (PCIA)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Postoperative pain status at 4 weeks
Number of subjects: 168
Study: 31640594

Group type: EXPERIMENTAL
Intervention: Mid-life 25(OH) D concentrations
Number of subjects: 13039
Study: 31640726

Group type: EXPERIMENTAL
Intervention: Natural course of unruptured intracranial aneurysms (UIAs)
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Risk factors for rupture of UIAs
Number of subjects: 5000
Study: 31640741

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.454% w/w stannous fluoride (1100 ppm fluoride), used twice daily for 24 weeks
Number of subjects: 75
Study: 31641390

Group type: EXPERIMENTAL
Intervention: Oncoxin (ONCX)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control (CT only)
Number of subjects: 133
Study: 31641582

Group type: EXPERIMENTAL
Intervention: Microbiome analysis of the nasopharynx and oropharynx
Number of subjects: 10
Study: 31641633

Group type: EXPERIMENTAL
Intervention: Saxagliptin as add-on to metformin
Number of subjects: 1109
Study: 31641952

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 100
Study: 31642041

Group type: EXPERIMENTAL
Intervention: Molecular kit (EuSepScreen lattanti)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Blood culture (BC)
Number of subjects: 69
Study: 31642045

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 646

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 646
Study: 31642213

Group type: EXPERIMENTAL
Intervention: SS (SYNTAX Score)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: SS II (SYNTAX Score II)
Number of subjects: 1248
Study: 31642446

Group type: EXPERIMENTAL
Intervention: Galectin-3 (Gal-3)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: soluble ST2 (sST2)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: sST2
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Galectin-3 (Gal-3) and soluble ST2 (sST2)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Primary endpoint (CV death or HF hospitalization)
Number of subjects: 117
Study: 31642523

Group type: EXPERIMENTAL
Intervention: Serum HA
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: PRO-C3
Number of subjects: 809

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 809
Study: 31642899

Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 1003
Study: 31642902

Group type: COMPARATOR
Intervention: Uncomplicated T2DM
Number of subjects: 193

Group type: COMPARATOR
Intervention: T2DM with albuminuria
Number of subjects: 193

Group type: COMPARATOR
Intervention: T2DM with retinopathy
Number of subjects: 193
Study: 31642983

Group type: EXPERIMENTAL
Intervention: Increase of 100 kcal from sugar per day
Number of subjects: 809
Study: 31644329

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 39
Study: 31644328

Group type: EXPERIMENTAL
Intervention: MRD-based treatment stratification after induction treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensified treatment directly after induction for very poor responders
Number of subjects: 0
Study: 31644380

Group type: EXPERIMENTAL
Intervention: Urban Zen Integrative Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31644538

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt insertion
Number of subjects: 89
Study: 31644841

Group type: EXPERIMENTAL
Intervention: Experiential Avoidance (EA)
Number of subjects: 183
Study: 31645407

Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) in patients with diabetes
Number of subjects: 3535

Group type: COMPARATOR
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) in patients without diabetes
Number of subjects: 3535
Study: 31645991

Group type: EXPERIMENTAL
Intervention: 15 SMS behaviour change communication messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: eVoucher for return transportation to CCS plus the same 15 SMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: One SMS informing about the nearest CCS clinic
Number of subjects: 0
Study: 31646098

Group type: EXPERIMENTAL
Intervention: tremelimumab and interferon-α (IFN)
Number of subjects: 33
Study: 31646195

Group type: EXPERIMENTAL
Intervention: Preterm newborns with bronchopulmonary dysplasia (BPD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Preterm newborns without bronchopulmonary dysplasia (BPD)
Number of subjects: 83
Study: 31646200

Group type: EXPERIMENTAL
Intervention: Faecal pH measurement
Number of subjects: 100
Study: 31646214

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual health plan outreach
Number of subjects: 0
Study: 31646465

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (8-week regimen)
Number of subjects: 230
Study: 31647026

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy for 1 year
Number of subjects: 1

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Gemcitabine-carboplatin-iniparib (GCI)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Radiotherapy (XRT)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Experimental vaccine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Tumor mutational burden
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: TiME biomarkers (CD8, ICs, PD-L1 on IC)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Immune-related RNA signatures
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: TNBC subtyping
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Genomic profiling
Number of subjects: 1
Study: 31647326

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31647530

Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiogram (SAECG) in Group 1 (patients with BrS)
Number of subjects: 250
Study: 31647861

Group type: EXPERIMENTAL
Intervention: Benzyl isothiocyanate (BITC)
Number of subjects: 0
Study: 31648294

Group type: EXPERIMENTAL
Intervention: CD19-directed chimeric antigen receptor-modified T (CAR-T) cells, 2 × 10^6 cells per kilogram after lymphodepletion with cyclophosphamide and fludarabine
Number of subjects: 21
Study: 31648325

Group type: EXPERIMENTAL
Intervention: Blinatumomab treatment
Number of subjects: 90
Study: 31648761

Group type: EXPERIMENTAL
Intervention: Blinded iFR pull back after angiographically successful PCI
Number of subjects: 500
Study: 31648999

Group type: EXPERIMENTAL
Intervention: Osimertinib at the dose of 80 mg/d
Number of subjects: 150
Study: 31649017

Group type: EXPERIMENTAL
Intervention: Household contacts exposed to multidrug resistant tuberculosis
Number of subjects: 10160

Group type: COMPARATOR
Intervention: Household contacts exposed to drug sensitive tuberculosis
Number of subjects: 10160
Study: 31649025

Group type: EXPERIMENTAL
Intervention: Takayasu's arteritis (TAK)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Giant cell arteritis (GCA)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both TAK and GCA
Number of subjects: 110
Study: 31650066

Group type: EXPERIMENTAL
Intervention: TetMYB vaccine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TetMYB vaccine and Anti-PD-1 antibody
Number of subjects: 32
Study: 31650067

Group type: EXPERIMENTAL
Intervention: Modified Tai Chi Qigong intervention (TCQ)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Intensity-matched body training intervention (BT)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 166
Study: 31650077

Group type: EXPERIMENTAL
Intervention: Innovative combination intervention to improve access to pediatric cancer services and treatment adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31650161

Group type: EXPERIMENTAL
Intervention: Glycated Albumin (GA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Fructosamine
Number of subjects: 150
Study: 31650176

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (HD-Cy) (3 g/m2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (LD-Cy) (≤1.5 g/m2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T-cell therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dose intensity of conditioning chemotherapy and minimal pretreatment disease burden
Number of subjects: 25
Study: 31650393

Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Age, diabetes duration, BMI, HbA1c, use of metformin, sulfonylurea derivatives, and DPP4 inhibitors
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: LDL cholesterol and serum creatinine
Number of subjects: 929
Study: 31650889

Group type: EXPERIMENTAL
Intervention: Threat interpretation bias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benign interpretation bias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual differences
Number of subjects: 0